UPDATE: Cowen Starts Novavax (NVAX) at Outperform

(Updated - January 21, 2022 6:01 AM EST)

Cowen analyst Georgi Yordanov initiates coverage on Novavax (NASDAQ: NVAX) with a Outperform rating.

The analyst comments "Novavax is entering the competitive COVID-19 vaccine market with a differentiated profile with improved tolerability compared to the mRNA options. Given the near-term cashflow from APAs and the potential to capture a share of what we believe will be an eventual post-pandemic annual vaccination market, we initiate at Outperform with a PT of $150. NanoFlu should provide downside protection."

For an analyst ratings summary and ratings history on Novavax click here. For more ratings news on Novavax click here.

Shares of Novavax closed at $90.36 yesterday.

You May Also Be Interested In

• UPDATE: Oppenheimer Starts Bentley Systems Inc. (BSY) at Outperform
• ABN Amro (ABN:NA) (ABNRY) PT Lowered to EUR11.40 at UBS
• Well Health Technologies Corp. (WELL:CN) (WLYYF) PT Lowered to Cdn$7 at TD Securities